An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data (EYEGUARD™-E)

XOMA

Status and phase: Terminated; Phase 3

Conditions: Uveitis

Treatments: Drug: Dose 2 gevokizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT02258854

X052132

Details and patient eligibility

About

The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.

Enrollment: 69 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Completed either the X052130/CL3-78989-005 or the X052131/CL3-78989-006 study's masked D392 or OL-224 completion day visits or had controlled ocular inflammation after having received study drug in Part 2 of study X052133

Exclusion criteria

• Discontinued from the previous study

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

69 participants in 1 patient group

Dose 2 gevokizumab

Experimental group

Treatment:

Drug: Dose 2 gevokizumab